Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab, Apatinib, and SBRT in HCC with PVTT
NCT04165174Phase 2Unknown
- Sponsor
- Huazhong University of Science and Technology
- Start
- Dec 2019
- Primary completion
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in hepatocellular carcinoma (HCC), sponsored by Huazhong University of Science and Technology. Primary endpoint: Progression-Free Survival at 3 years. Status: unknown.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04165174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04165174.